NEW YORK (GenomeWeb) – Intellia Therapeutics has filed a preliminary prospectus for an initial public offering worth up to $120 million. The firm has separately announced a licensing and collaboration agreement with Regeneron Pharmaceuticals for in vivo therapeutic development with a focus on liver diseases that is potentially worth billions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.